Hanmi Pharm Co's basic earnings per share (Basic EPS) for the
three
months ended in Mar. 2026 was ₩3,586.00.
Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was ₩13,598.00.
Hanmi Pharm Co's EPS (Diluted) for the
three
months ended in Mar. 2026 was ₩3,586.00.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₩13,588.00.
Hanmi Pharm Co's EPS without NRI for the
three
months ended in Mar. 2026 was ₩4,190.14.
Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 17,101.41.
During the past 12 months, Hanmi Pharm Co's average EPS without NRIGrowth Rate was 71.20% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 30.40% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 50.70% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 10.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, Hanmi Pharm Co's highest 3-Year average EPS without NRI Growth Rate was 100.00% per year. The lowest was -39.90% per year. And the median was 22.20% per year.
Hanmi Pharm Co (XKRX:128940) EPS (Basic) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Hanmi Pharm Co EPS (Basic) Related Terms
Hanmi Pharm Co EPS (Basic) Historical Data
* Premium members only.
The historical data trend for Hanmi Pharm Co's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
Hanmi Pharm Co's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as
EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩13,598.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hanmi Pharm Co (XKRX:128940) has a EPS (Basic) of ₩13,598.00 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Hanmi Pharm Co and its competitors.
Is Hanmi Pharm Co's EPS (Basic) too high?
Hanmi Pharm Co's current EPS (Basic) is ₩13,598.00. Overall, Hanmi Pharm Co has a GF Score™ of 95/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hanmi Pharm Co's EPS (Basic) compare to ZTS?
Hanmi Pharm Co's EPS (Basic) of ₩13,598.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Hanmi Pharm Co and its competitors. Hanmi Pharm Co's current EPS (Basic) is ₩13,598.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hanmi Pharm Co stock overvalued right now?
Based on GuruFocus' analysis, Hanmi Pharm Co (XKRX:128940) is currently considered Modestly Overvalued. The stock's GF Value™ is ₩332,913.08, compared to a current price of ₩394,000.00 — trading 18.3% above its estimated fair value. The current EPS (Basic) is ₩13,598.00. Hanmi Pharm Co's overall GF Score™ is 95/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Hanmi Pharm Co (XKRX:128940), the current EPS (Basic) is ₩13,598.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hanmi Pharm Co (XKRX:128940) Overvalued in 2026?
Based on GuruFocus' analysis, Hanmi Pharm Co stock appears to be overvalued.
The current stock price of ₩394,000.00 is trading 18.3% above its estimated GF Value™ of ₩332,913.08.
GuruFocus considers Hanmi Pharm Co to be Modestly Overvalued.
Key valuation signals for XKRX:128940:
EPS (Basic): ₩13,598.00
GF Value™: ₩332,913.08 vs. price of ₩394,000.00 (18.3% above fair value)
No single metric tells the full story. See the XKRX:128940 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hanmi Pharm Co Ltd is a Korea-based company, engaged in manufacturing and marketing of medicines, medical supplies and raw materials for medicines. The company makes strenuous and enthusiastic efforts to develop treatments for diabetes, obesity, cancer, autoimmune and rare disease to keep everyone's health and improve their quality of life. The group distributes its products within Korean market and to overseas markets.
95GF Score
Get the complete analysis for XKRX:128940
EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:128940 has been successfully added to your 
